CHMP recommends Raxone (idebenone) to treat Leber's Hereditary Optic Neuropathy (LHON)- Santhera
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for Raxone (idebenone) from Santhera for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).LHON is a heritable mitochondrial disease that leads to rapid, profound and usually permanent blindness in otherwise healthy patients. Raxone will be the first treatment option for LHON and the first approved therapy for a mitochondrial disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins